Practical solutions for today's world
A novel metabolic research approach to Chronic Kidney Disease (CKD)
Chronic Kidney Disease remains a major global health challenge. Despite important advances in nephroprotective strategies, patients—particularly those with advanced CKD—continue to face substantial residual risk of disease progression and complications.
Virtus Humanitatis investigates complementary metabolic approaches focused on mitochondrial function and the Tricarboxylic Acid (TCA) Cycle.
The complexity of CKD management
CKD management is inherently multifactorial and may involve management of blood pressure, glycemic control, electrolyte and acid-base disturbances, anemia, mineral and bone disorders, nutritional status, and the underlying causes and comorbidities associated with kidney disease.
In addition to the medication needed to manage these parameters, patients need to continue with their medicines to treat the disease causing CKD, predominantly diabetes and hypertension.
As CKD advances, treatment regimens can become increasingly complex, adding to the burden experienced by patients and caregivers.
A published retrospective observational study evaluated changes in multiple renal and metabolic parameters in patients receiving the studied formulation.
Our Team
Virtus Humanitatis was founded in 2015 by physicians with backgrounds in Nephrology, Endocrinology and Internal Medicine, following several years of research into metabolic abnormalities associated with Chronic Kidney Disease and potential complementary approaches to its management.
Current CKD management combines treatment of the underlying disease with established nephroprotective strategies and management of metabolic complications.
At Virtus Humanitatis, we have developed and patented a metabolic formulation based on intermediates of the Tricarboxylic Acid (TCA) Cycle, a central mitochondrial metabolic pathway. This composition has been clinically evaluated in patients with stages 3b, 4 and 5 Chronic Kidney Disease.
Partnering
Virtus Humanitatis is seeking strategic partners for licensing, clinical development and commercialization of its patented renal metabolic technology.
Our patented renal metabolic composition is protected across multiple international markets, including the United States, China, Japan and Mexico.
In 2024, our research team published a retrospective observational study evaluating the formulation in 55 patients with stages 3b, 4 and 5 CKD. Statistically significant changes were observed in eGFR, serum creatinine, urea, phosphorus and hemoglobin during the evaluated period.
These findings are observational and require confirmation in prospective controlled clinical studies.
Interested in innovating for today's world? Contact Us
